KR20090096776A - Red coji ginseng and the producing method therof - Google Patents
Red coji ginseng and the producing method therof Download PDFInfo
- Publication number
- KR20090096776A KR20090096776A KR1020080021802A KR20080021802A KR20090096776A KR 20090096776 A KR20090096776 A KR 20090096776A KR 1020080021802 A KR1020080021802 A KR 1020080021802A KR 20080021802 A KR20080021802 A KR 20080021802A KR 20090096776 A KR20090096776 A KR 20090096776A
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- content
- gaba
- ginseng
- red
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 241000208340 Araliaceae Species 0.000 title description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 title description 17
- 235000008434 ginseng Nutrition 0.000 title description 17
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 102
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 46
- 235000021329 brown rice Nutrition 0.000 claims abstract description 13
- 241000030999 Monascus pilosus Species 0.000 claims abstract description 9
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims abstract description 5
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 5
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 15
- 229940057059 monascus purpureus Drugs 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 abstract description 10
- 229930182494 ginsenoside Natural products 0.000 abstract description 6
- 229940089161 ginsenoside Drugs 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 description 15
- 239000013543 active substance Substances 0.000 description 8
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 6
- 229930000044 secondary metabolite Natural products 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 4
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000113306 Monascus purpureus Species 0.000 description 2
- 235000002322 Monascus purpureus Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000007189 Oryza longistaminata Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940043353 maltol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940026314 red yeast rice Drugs 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 GABA와 모나콜린 K 함량을 증대시킨 고기능성 홍국 홍삼 및 그 제조방법에 관한 것이다.The present invention relates to a high-functional red ginseng red ginseng with an increased content of GABA and monacoline K and a preparation method thereof.
일반적으로 홍삼이란 수삼을 껍질째 건조시켜 수분 함량 14% 이하가 되도록 가공한 것으로서, 제조과정 중 갈색화 반응이 촉진되어 농다갈색의 색상을 띠며, 매우 단단한 형태로 원형을 유지시킨 인삼을 말한다. 홍삼은 제조과정에서 열분해에 의하여 성분의 부분 구조 변화가 일어나 인체에 유익한 특수 성분이 생성되는데, 이는 수삼이나 백삼 등 다른 인삼에는 들어있지 않고 홍삼에만 들어있는 것으로 노화 억제성분(말톨, Maltol), 암세포 증식억제성분 및 항종양성분, 암세포 전이 억제 성분 등이 함유되어 있다. 홍삼은 항균성분, 항암성분, 혈당강화성분, 비만억제성분, 노화억제성분, 중금속해독성분 등의 특수성분을 함유하고 있다. 그리고, 홍삼은 제조과정에서 인삼조직 중의 전분 입자가 졸(Sol) 상태에서 겔(Gel) 상태로 전환되기 때문에 인삼보다 소화흡수가 잘 되고, 인삼은 껍질 바로 안쪽에 여러 가지 유효성분들이 축적되어 있는 망상조직이 존재하는데 홍삼은 이와 같은 유 효성분이 축적되어 있는 껍질(망상조직)을 벗기지 않고 가공하므로 유효성분의 함량이 높아 효능이 우수하다. 또한, 홍삼은 제조과정에서 증숙 공정을 거치게 되는데 이때 조직 중의 전분 입자가 호화되어 건조 후에 조직이 견고해지는데 증숙 공정을 거치는 동안 각종 효소들이 불활성화되어 자가소화작용이 일어나지 않게 되므로 품질 안정성이 우수하고 장기간 보관해도 내용성분의 변화가 없는 특징이 있다.Generally, red ginseng is dried ginseng as a bark and processed to have a water content of 14% or less. The ginseng has a dark brown color, which is promoted by the browning reaction during the manufacturing process, and refers to ginseng that maintains a very solid form. Red ginseng is a part of the structural structure of the product due to thermal decomposition during the manufacturing process to produce a special ingredient that is beneficial to the human body, which is contained only in red ginseng, not in other ginseng such as ginseng or white ginseng, anti-aging ingredients (maltol, Maltol), cancer cells Proliferation inhibitory ingredient, antitumor ingredient, cancer cell metastasis suppression ingredient are contained. Red ginseng contains special ingredients such as antibacterial ingredients, anticancer ingredients, blood sugar enhancing ingredients, anti-obesity ingredients, anti-aging ingredients, and heavy metal poisoning ingredients. In addition, red ginseng is more easily digested and absorbed than ginseng because starch particles in ginseng tissues are converted from a sol state to a gel state. There is a reticulum, and red ginseng is processed without peeling the bark (the reticular tissue) in which such an active ingredient is accumulated, so the content of the active ingredient is high and the efficacy is excellent. In addition, red ginseng undergoes a steaming process in the manufacturing process, where the starch particles in the tissues are gelatinized and the tissues are solid after drying. During the steaming process, various enzymes are inactivated so that auto-digestion does not occur. Even if it is stored for a long time, it does not change its contents.
홍국(紅麴, MONACUS PILOSUS)은 된장, 간장, 청주 등의 양조식품에 사용되는 누룩의 일종으로 균사가 붉은색을 띠고 있기 때문에 홍국이라고 부르며, 한국을 비롯하여 중국, 홍콩, 일본 및 대만 등에서 오래전부터 전통식품에 사용해왔다. 예로부터 중국과 대만에서는 홍국을 여러 종류의 발효식품에 사용해 오고 있으며, 술, 홍유부, 야채 등은 그 대표적인 식품으로서 착색 및 방부목적으로 홍국을 사용해 왔다. 일본에서는 1970년대 들어 식품첨가물로 사용돼 오던 일부 타르계 합성착색료의 안전성이 문제가 되면서 홍국을 천연색소로서 이용하게 되어 그 소비량이 매년 증대되고 있다. 특히 고지혈증, 심혈관 질환, 뇌혈관질환, 동맥경화, 고혈압, 저혈압, 협심증, 뇌졸중, 당뇨, 지방간, 비만, 고혈당증 등의 만성질환 예방, 치료 및 혈중 콜레스테롤 저하에 탁월한 효과를 보이는 모나콜린 K 뿐만 아니라 이와 유사한 구조를 지니면서 생리활성효과가 유사한 동일계의 다른 활성물질들이 다량 존재한다. 홍국이 생성하는 색소성분은 항암, 항균 및 항산화효과가 있으며 천연색소, 기능성 식품원료로서 햄이나 소시지 등의 육가공품에도 적용하고 된장과 고추장을 비롯하여 식초, 두부, 간장, 음료수 및 빵 등에 첨가하고 있을 만큼 널리 알려져 있다.Hongguk (MONACUS PILOSUS) is a type of yeast used for brewed foods such as miso, soy sauce, and sake. It is called hongguk because mycelia have a red color, and it has been known for a long time in Korea, China, Hong Kong, Japan and Taiwan. It has been used in traditional foods. Since ancient times, red yeast soup has been used in various kinds of fermented foods in China and Taiwan, and sake, red yubu and vegetables have been used for coloring and preservative purposes as representative foods. In Japan, the safety of some tar-based synthetic coloring materials, which have been used as food additives since the 1970s, has become a problem, and the consumption of red rice is used as a natural pigment. Not only monacoline K, which has excellent effects on the prevention and treatment of chronic diseases such as hyperlipidemia, cardiovascular disease, cerebrovascular disease, arteriosclerosis, hypertension, hypotension, angina pectoris, stroke, diabetes, fatty liver, obesity, hyperglycemia, and lowering blood cholesterol. There is a large amount of other active substances in the same line having a similar structure and similar bioactive effects. The pigments produced by red yeast soup have anti-cancer, antibacterial and antioxidant effects. They are applied to processed meat products such as ham and sausages as natural pigments and functional foods, and are added to miso and red pepper paste, vinegar, tofu, soy sauce, drinks and bread. As widely known.
GABA는 γ-아미노부티르산(Gamma-Amino Butyric Acid; 이하 "GABA"라 함)의 약자이며, 억제성 신경전달물질로서 뇌 혈류개선, 산소공급 증가, 뇌세포 대사기능을 촉진시켜 신경안정작용, 스트레스 해소, 기억력 증진, 혈압강하작용, 우울증 완화, 중풍과 치매예방, 불면, 비만, 갱년기 장애 등에 효과가 있는 것으로 알려져 있으며, 최근 뇌졸중 및 결장암, 대장암 세포의 전이 및 증식억제효과가 있는 것으로 밝혀지고 있다. 식물에서는 해충의 공격이나 종자의 발아시 또는 기계적 자극, 온도, 수분, 빛, 산소, 등의 여러 외부환경요인에 의해 그 함량이 급격히 증진되므로, 식물세포의 활성화를 통한 성장과 자기보호기능에 중요한 역할을 하게 된다. 따라서, 식물체에서 GABA는 외부환경을 적절히 조절하여 줌으로써, 그 함량을 크게 증진시킬 수 있는 물질인 것으로 알려져 있다.GABA is an abbreviation of γ-aminobutyric acid (hereinafter referred to as "GABA"). It is an inhibitory neurotransmitter that stimulates brain blood flow, increases oxygen supply, and promotes brain cell metabolism, resulting in neurostable action and stress. It is known to be effective in relieving, improving memory, lowering blood pressure, reducing depression, preventing stroke and dementia, insomnia, obesity, and menopausal disorders. Recently, it has been shown to have an effect of inhibiting metastasis and proliferation of stroke, colon and colon cancer cells. have. In plants, their contents are rapidly increased by insect attack or germination of seeds, or by various external environmental factors such as mechanical stimulation, temperature, moisture, light, oxygen, etc., which are important for growth and self-protection through activation of plant cells. It will play a role. Therefore, GABA in plants is known to be a substance that can greatly enhance its content by appropriately controlling the external environment.
GABA는 식품소재, 건강보조식품, 기능성 식품, 약, 우유, 과자, 마요네즈, 죽, 떡, 발효유, 드링크, 김치, 현미, 두부, 낫토, 두유 등에 적용되고 있고, 기능성 식품의 성분으로 그 활용성이 증가하고 있다.GABA is applied to food materials, health supplements, functional foods, medicines, milk, sweets, mayonnaise, porridge, rice cakes, fermented milk, drinks, kimchi, brown rice, tofu, natto, soy milk, etc. This is increasing.
최근에 이르러서는 소비자의 관심이 질 높은 건강 기능성 제품을 요구하고 있으나 GABA와 모나콜린 K와 같은 기능성 성분이 충분히 함유된 홍삼에 관한 연구는 아직 미흡하다. 특허 제635132호는 홍국인삼 제조방법에 관한 것으로서, 20~30℃로 2~7일간 배양한 홍국균을 증자된 쌀에 접종하여 20~30℃로 7~20일간 고체배양한 후 인삼에 상기 고체배양된 홍국균을 접종하여 20~30℃로 7~20일간 배양하여 홍국 인삼을 제조하는 방법을 개시하였다. 그러나, 이와 같은 제조 방법은 모나콜린 K의 함량이 0.3% 이하로서 낮아 이를 개선하여 함량을 높이는 방법이 필요하다. In recent years, consumer interest demands high quality health functional products, but studies on red ginseng containing sufficient functional ingredients such as GABA and Monacholine K are still insufficient. Patent No. 635132 relates to a method for producing red ginseng ginseng, inoculated with red rice bacteria cultured at 20 to 30 ° C. for 2 to 7 days in a cooked rice, followed by solid culture at 20 to 30 ° C. for 7 to 20 days, and the solid culture to ginseng. Inoculated with the hongguk bacteria was incubated for 7 to 20 days at 20 ~ 30 ℃ to disclose a method for producing red ginseng ginseng. However, such a manufacturing method requires a method of increasing the content by improving the content of Monacholine K is less than 0.3%.
상기와 같은 종래기술의 문제점을 해결하고자, 본 발명은 홍삼에 홍국균의 고체배양기술을 이용하여 GABA와 모나콜린 K 성분이 증진된 고기능성 홍국 홍삼을 제조하는 방법을 제공하는 것을 목적으로 한다.In order to solve the problems of the prior art as described above, an object of the present invention is to provide a method for producing high functional red ginseng red ginseng with enhanced GABA and Monacholine K components by using the solid culture technology of red ginseng bacteria in red ginseng.
본 발명의 다른 목적은 상기 제조방법으로 홍삼의 유효성분인 진세노사이드 8종 성분이 강화되고 홍국의 신경안정효과를 가지는 GABA와 혈중콜레스테롤 저하물질인 모나콜린 K의 함량이 증대된 고기능성 홍국 홍삼을 함유한 기능성 식품 및 미용제품을 제공하는 것이다.Another object of the present invention is a high-functional red ginseng red ginseng which is enhanced in the ginsenoside eight components of the red ginseng by the preparation method and the content of GABA having a neurostable effect of red ginseng and monacholine K that is a blood cholesterol-lowering substance It is to provide a functional food and beauty products containing.
상기 목적을 달성하기 위하여, 본 발명은 홍삼에 현미가루를 혼합 후 홍국균을 접종하여 고체배양을 하는 것을 특징으로 하는 고기능성 홍국 홍삼의 제조방법을 제공한다.In order to achieve the above object, the present invention provides a method for producing a high-performance red ginseng red ginseng, characterized in that the solid culture by inoculating the red ginseng and inoculated with red ginseng.
본 발명은 홍삼에 홍국을 고체배양기술을 접목하여 고기능성 홍국 홍삼 제조 방법으로 GABA와 모나콜린-K 함량을 증가시키고, 진세노사이드 성분 중 Rg3, Rh1을 증가시키는 고기능성 홍국 홍삼의 제조방법을 제공한다. 또한 홍삼에 홍국을 고체 발효하여 홍삼의 약리 작용과 효능에 홍국의 신경안정 효과를 가지는 GABA와 혈중콜레스테롤 저하물질인 모나콜린 K 함량이 증진된 홍국 홍삼 제조로 건강증진 및 성인병 예방을 위한 기능성 식품을 제공할 수 있다.The present invention is a method of producing a high-functional red ginseng red ginseng by increasing the content of GABA and monacholine-K, and increase the Rg3, Rh1 of ginsenosides by combining the red culture of red ginseng with solid culture technology to red ginseng to provide. In addition, red ginseng is solid fermented into red ginseng, and GABA has a neurostable effect on red ginseng's pharmacological effects and efficacy, and red ginseng red ginseng with enhanced monacholine K content, a blood cholesterol-lowering substance, provides functional foods for health promotion and adult disease prevention Can provide.
본 발명은 홍삼에 현미가루를 혼합하여 수분 함량을 35~50%로 조절한 후 홍국균 모나스커스 필로수스(Monascus pilosus)를 초기 산도 pH 5 조건에서 30~35℃로 10~40일간 고체배양하는 단계를 포함하는 GABA와 모나콜린 K 함량을 증대시킨 고기능성 홍국 홍삼 제조방법을 제공한다.In the present invention, the red ginseng is mixed with brown rice powder to adjust the moisture content to 35 to 50%, followed by the step of culturing the solids of the red yeast bacterium Monascus pilosus at 30 to 35 ° C. under an initial pH of 5 for 10 to 40 days. It provides a high-functional red ginseng red ginseng production method to increase the GABA and Monacholine K content.
또한, 본 발명은 상기 홍삼이 4번 이상 증숙 및 건조한 것임을 특징으로 한다.In addition, the present invention is characterized in that the red ginseng steamed and dried four or more times.
또한, 본 발명은 상기 홍국균 고체배양 이후에 배양온도를 25~29℃로 낮추어 배양함을 특징으로 한다.In addition, the present invention is characterized by culturing by lowering the culture temperature to 25 ~ 29 ℃ after the hongkuk solid culture.
또한, 본 발명은 상기 고체배양 3일 이후에 글루탐산 나트륨 0.1~0.3%(w/w)을 첨가하는 것을 특징으로 한다.In addition, the present invention is characterized in that the sodium glutamate 0.1 to 0.3% (w / w) is added after 3 days of the solid culture.
뿐만 아니라, 본 발명은 상기 방법으로 제조되며, GABA 200mg/100g 이상, 모나콜린 K 200mg/100g 이상을 함유하는 것을 특징으로 하는 고기능성 홍국 홍삼을 제공한다.In addition, the present invention is prepared by the above method, GABA provides a high-performance red ginseng red ginseng, characterized in that containing 200mg / 100g or more, Monacholine K 200mg / 100g or more.
본 발명에 의한 바람직한 홍국 홍삼 제조방법을 자세히 설명한다.It will be described in detail a preferred method for producing red yeast red ginseng according to the present invention.
먼저 홍삼을 준비한다. 수삼을 세척하여 4번 찌고 4번 냉동 건조하여 수분함량이 15% 이하로 제조된 홍삼을 준비한다.First, prepare red ginseng. Wash red ginseng 4 times and freeze-dried 4 times to prepare red ginseng with less than 15% moisture content.
그 다음으로는 홍삼을 당에 침지한다. 50%(w/v) 설탕물에 상기 4증4포된 홍삼을 한 시간 동안 침지한다.Next, red ginseng is dipped in sugar. The four-packed red ginseng is soaked in 50% (w / v) sugar water for one hour.
상기 당침된 홍삼을 채반에 올려놓고 6시간 동안 물기를 제거한다.Place the acupuncture red ginseng on the tray and remove the water for 6 hours.
100~150mesh 정도로 분쇄된 현미가루를 물기가 제거된 홍삼 중량의 10%(w/w)만큼 넣고 혼합한다.Add brown rice powder pulverized about 100 ~ 150mesh by 10% (w / w) of the weight of red ginseng.
혼합된 현미와 홍삼을 버섯배양용 용기에 넣은 후 멸균기 안에서 121℃로 20분 동안 멸균한다.The mixed brown rice and red ginseng are put into a mushroom culture container and sterilized at 121 ° C. for 20 minutes in a sterilizer.
PD 브로쓰 배지에 모나스커스(Monascus) 균주를 접종하여 30℃, 150rpm의 진탕배양기에서 5일 동안 배양한다.Monascus strains were inoculated in PD broth medium and incubated at 30 ° C. and 150 rpm for shaking for 5 days.
멸균된 홍삼에 상기 배양된 홍국균 즉 모나스커스 균주를 중량대비 10% 접종한 후 고체배양실에서 10~15일 동안 배양한다. 단, 배양 3일 동안 30~35℃온도를 유지하고, 그 이후부터는 25~28℃로 온도를 낮추어 배양하며, 백열등으로 광처리하여 고체배양한다.After inoculating 10% by weight of the cultured red ginseng bacterium, ie Monascus strain, into sterile red ginseng and incubated in a solid culture room for 10-15 days. However, the culture is maintained at 30 ~ 35 ℃ temperature for 3 days, after that the temperature is lowered to 25 ~ 28 ℃ culture, and incubated by incandescent light to incubate solid.
이와 같이 배양한 경우 종래의 홍국 홍삼 배양에 비하여 GABA와 모나콜린 K의 함량이 현저히 증가되고, 진세노사이드 Rg3. Rh1의 함량이 증대된 홍국 홍삼을 얻을 수 있다.When cultured in this way, the content of GABA and Monacholine K is significantly increased compared to conventional red ginseng red ginseng culture, ginsenoside Rg3. Red ginseng red ginseng with an increased content of Rh1 can be obtained.
이하, 실시예를 통하여 본 발명의 구성을 좀더 자세히 설명한다. 그러나, 본 발명의 범위가 아래 실시예의 기재에만 한정되는 것이 아님은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명하다.Hereinafter, the configuration of the present invention through the embodiment in more detail. However, it will be apparent to those skilled in the art that the scope of the present invention is not limited only to the description of the following examples.
실시예Example 1: One: 홍국균Red yeast 균주 선발 Strain Selection
고기능성 홍국 홍삼을 제조할 수 있는 균주를 선발하기 위하여 홍국 생산에 사용되어 온 식품미생물인 다양한 모나스커스(Monascus) 균주를 시험에 사용하였다. 홍삼에 홍국을 접종하여 10일 고체배양한 후 GABA 및 모나콜린 K 함량을 측정하였다.In order to select strains capable of producing highly functional red ginseng red ginseng, various Monascus strains, which are food microorganisms that have been used to produce red ginseng, were used for the test. The red ginseng was inoculated with red yeast rice, followed by solid culture for 10 days, and then the GABA and monacholine K contents were measured.
표 1에 나타난 바와 같이, 모나스커스 필로수스(Monascus pilosus)가 다른 모나스커스 속 균주(Monascus.sp)보다 활성물질인 GABA와 모나콜린 K의 함량이 높은 홍국 홍삼을 생산함을 알 수 있었다.As shown in Table 1, Monascus pilosus (Monascus pilosus) was found to produce red ginseng red ginseng with a higher content of GABA and Monacholine K active material than other Monascus strain (Monascus.sp).
실시예Example 2: 홍삼 재료 선발 2: Selection of Red Ginseng Ingredients
모나스커스 필로수스(Monascus pilosus) KCCM 60084를 사용하여 증숙-건조횟수가 다른 홍삼에 접종하여 활성물질인 GABA와 모나콜린-K의 함량을 비교하였다.Monascus pilosus KCCM 60084 was used to inoculate red ginseng with different steaming-drying times to compare the contents of GABA and monacoline-K.
표 2 결과에서 보듯이 다소 차이는 없었지만 홍국 홍삼의 성상과 활성물질 함량, 진세노사이드 함량 그리고 생산성을 고려할 때 4증 4포, 5증 5포, 6증 6포 홍삼이 적절한 재료임을 알 수 있었다.As shown in the results of Table 2, 4 ginseng, 4 ginseng, 5 ginseng, 6 ginseng and 6 ginseng red ginseng were considered appropriate ingredients in consideration of the characteristics, active substance content, ginsenoside content and productivity of red ginseng red ginseng. .
실시예Example 3: 고체배양조건 확립 3: Establish solid culture conditions
GABA와 모나콜린 K 함량이 증가된 고기능성 홍국 홍삼을 제조하기 위한 고체배양조건을 확립하기 위해서 고체배양 혼합기질조성비, 배양 온도 전환, pH, 수분함량, 첨가배지조성, 광처리, 배양시간 등을 변화시키면서 결과를 비교하였다.To establish solid culture conditions for the production of highly functional red ginseng red ginseng with increased GABA and Monacholine K content, changes in solid culture mix substrate composition, incubation temperature conversion, pH, moisture content, addition medium composition, light treatment, and incubation time The results were compared.
실시예Example 3-1: 고체배양 혼합기질 3-1: Solid Culture Mixed Substrate
GABA와 모나콜린 K 함량을 향상시키기 위해서 홍삼과 다양한 곡류를 대상으로 적합성이 뛰어난 기질을 검토한 후 기능성 함량을 비교하였다.To improve GABA and Monacholine K content, red ginseng and various grains were examined for their suitability and compared with their functional content.
상기 표 3에서 보듯이, 현미가루를 첨가한 경우가 곡분을 첨가하지 않은 경우보다 활성물질 함량이 3~5배 높은 함량을 가진 홍국 홍삼을 제조할 수 있음을 알 수 있었다.As shown in Table 3, it was found that the red ginseng red ginseng having an active substance content of 3 to 5 times higher than the case where the brown rice flour was added was not added to the flour.
현미가루 첨가량은 홍삼 중량 100중량%를 기준으로 할 때 5~50중량%가 바람직한 것으로 나타났다(결과 미첨부). 현미가루가 5중량% 미만이면 GABA와 모나콜린 K의 함량 증가가 미미하며, 50중량%를 넘으면 현미가루 증대에 따른 GABA와 모나콜린 K의 함량 증대효과가 감소한다.The brown rice flour added amount was preferably 5 to 50% by weight based on 100% by weight of red ginseng (without results). If the brown rice flour is less than 5% by weight, the increase in the content of GABA and Monacholine K is insignificant. If the brown rice powder exceeds 50% by weight, the effect of increasing the content of GABA and Monacholine K is reduced by the increase in brown rice flour.
실시예Example 3-2: 고체배양 온도 전환 3-2: Solid Culture Temperature Conversion
고기능성 홍국 홍삼을 제조하기 위한 고체배양조건을 확립하기 위해서 배양 온도 전환에 따른 활성물질 함량 등을 비교하였다.In order to establish the solid culture conditions for the production of high-functional red ginseng red ginseng, the contents of the active substances were compared according to the culture temperature conversion.
고체배양 3일 동안은 35℃로 유지하다가 4일째 배양온도를 28℃로 전환하였을 때 온도 전환을 하지 않고 35℃로 유지하여 배양한 경우에 비하여 이차 대사산물인 GABA와 모나콜린 K의 함량이 1.5배 이상 증가함을 알 수 있었다.The content of secondary metabolites, GABA and Monacholine K, was 1.5 when the solid was maintained at 35 ° C. for 3 days and then cultured at 35 ° C. without changing the temperature when the culture temperature was changed to 28 ° C. on the fourth day. It was found to increase more than twice.
실시예Example 3-3: 고체배양 최적수분함량 확립 3-3: Establishment of Optimum Moisture Content in Solid Culture
고기능성 홍국 홍삼을 제조하기 위한 고체배양조건을 확립하기 위해서 고체배지 수분 함량에 따른 GABA와 모나콜린 K의 활성물질 함량 등을 비교하였다.In order to establish the solid culture conditions for the production of high functional red ginseng red ginseng, the contents of the active substances of GABA and Monacholine K were compared according to the solid medium moisture content.
고체배양의 초기수분함량을 비교한 결과, 40%에서 활성물질 함량이 최대로 증가함을 알 수 있었다.As a result of comparing the initial moisture content of the solid culture, it was found that the active substance content increased to the maximum at 40%.
실시예Example 3-4: 3-4: 고체배지Solid medium pHpH
고기능성 홍국 홍삼을 제조하기 위하여 고체배지의 초기 pH와 GABA와 모나콜린 K 함량을 비교하였다.To prepare high functional red ginseng red ginseng, the initial pH of the solid medium and the contents of GABA and Monacholine K were compared.
고체배양의 초기 pH를 비교한 결과, pH 4~5.5에서 활성물질이 가장 많이 생성됨을 알 수 있었다.As a result of comparing the initial pH of the solid culture, it was found that the most active material is produced at pH 4 ~ 5.5.
실시예Example 3-5: 고체배양 첨가 배지 확립 3-5: Establishment of Solid Culture Addition Medium
활성물질 함량을 증가시키기 위해서 홍삼과 발아현미 이외에 4종의 배지성분을 고체배양 3일 이후에 첨가함으로써, 이차대사산물인 GABA와 모나콜린 K 함량을 비교한 결과, 글루탐산나트륨을 첨가한 경우 무첨가보다 GABA와 모나콜린 K 함량이 2배 가량 증가됨을 알 수 있었다.In addition to the red ginseng and germinated brown rice to increase the active substance content, four media components were added after 3 days of solid culture, and as a result of comparing the secondary metabolite GABA and monacholine K content, when sodium glutamate was added, GABA and monacholine K content was found to be increased approximately 2 times.
실시예Example 3-6: 3-6: 광처리Light treatment
활성물질 함량을 증대시키기 위해서 고체배양 3일 후 광처리한 실험군과 무처리한 대조군을 비교한 결과, 이차대사산물인 가바와 모나콜린 K 모두 광처리한 실험군이 무처리한 대조군보다 1.5배 향상되었다. 이때 광처리 조건은 조도가 200~500 Lux로 고체배양기간 내내 연속적으로 처리한다.In order to increase the active substance content, the experimental group treated with the light treated group and the untreated control group after 3 days of solid culture showed that the experimental group treated with both the secondary metabolites Gaba and Monacholine K was 1.5 times higher than the untreated control group. At this time, the light treatment conditions are roughly 200 ~ 500 Lux is treated continuously throughout the solid culture period.
실시예Example 3-7: 고체배양 시간 3-7: solid culture time
배양일수에 따른 이차대사산물인 가바와 모나콜린 K 함량을 비교한 결과, 배양시간에 따라 이차대사산물의 함량이 증가됨을 알 수 있었다. 이때 배양 시간 외의 다른 조건은 상기 실시예 3-1 내지 3-6에서 얻어진 최적 조건을 적용하였다.As a result of comparing the content of Gaba and Monacholine K, the secondary metabolite according to the culture days, the content of the secondary metabolite increased with the incubation time. At this time, other conditions than the incubation time were applied to the optimum conditions obtained in Examples 3-1 to 3-6.
그 결과, 40시간 배양한 경우 GABA와 모나콜린 K의 함량이 가장 많음을 확인하였다.As a result, it was confirmed that the contents of GABA and Monacholine K were the highest when incubated for 40 hours.
실시예Example 4: 4: 홍국Red yeast rice 홍삼의 Red ginseng 가바Gava ,, 모나콜린Monacoline K, K, 진세노사이드Ginsenoside 함량 측정 Content measurement
상기 실시예 3-1 내지 3-7을 통하여 확립된 홍국 홍삼 고체배양조건은 기존 배양조건(홍삼에 혼합기질 없이 홍국균을 접종하여 24~35℃에서 배지 무첨가 및 광처리 없이 10일 동안 고체배양)에 비해 이차 대사산물인 GABA 또는 모나콜린 K의 함량이 20배 이상 증가함을 볼 수 있었고, 홍삼의 유효성분인 진세노사이드 중 Rg3와 Rh1은 기존 배양조건에 의하여 얻어지는 함량보다 상당량 증가함을 확인할 수 있었다.Hongguk red ginseng solid culture conditions established through Examples 3-1 to 3-7 are in the existing culture conditions (solid culture for 10 days without medium and light treatment at 24 ~ 35 ℃ by inoculating red ginseng without mixed substrate in red ginseng) Compared with the secondary metabolite GABA or Monacholine K, the content of GBA increased 20 times, and Rg3 and Rh1 in ginsenosides, the active ingredient of red ginseng, were significantly increased than those obtained by conventional culture conditions. there was.
도 1은 본 발명의 일 실시예에 의한 홍국 홍삼 제조방법을 도시한 것이다.1 illustrates a method for producing red ginseng red ginseng according to an embodiment of the present invention.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080021802A KR100970108B1 (en) | 2008-03-10 | 2008-03-10 | Red coji ginseng and the producing method therof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080021802A KR100970108B1 (en) | 2008-03-10 | 2008-03-10 | Red coji ginseng and the producing method therof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090096776A true KR20090096776A (en) | 2009-09-15 |
KR100970108B1 KR100970108B1 (en) | 2010-07-15 |
Family
ID=41356320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080021802A KR100970108B1 (en) | 2008-03-10 | 2008-03-10 | Red coji ginseng and the producing method therof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100970108B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101381090B1 (en) * | 2013-03-21 | 2014-04-04 | 계명대학교 산학협력단 | Method for producing fermented milk with high gaba and peptide content using serial fermentation of bacillus and lactococcus |
KR20220072474A (en) * | 2020-11-25 | 2022-06-02 | 대상 주식회사 | Medium Composition for Producing Monacolin K, Method for Preparing Fermented Substance Using Same and Fermented Substance Prepared Thereby |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100435267B1 (en) * | 2001-09-13 | 2004-06-11 | 박동기 | Method for the production of monascus inoculation germinated rice brown and it productive method for food |
KR100635132B1 (en) | 2004-09-10 | 2006-10-17 | 이인경 | Method for preparing of red-koji ginseng |
KR20060124336A (en) * | 2005-05-31 | 2006-12-05 | 홍림통산(주) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH gamma;-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA |
-
2008
- 2008-03-10 KR KR1020080021802A patent/KR100970108B1/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101381090B1 (en) * | 2013-03-21 | 2014-04-04 | 계명대학교 산학협력단 | Method for producing fermented milk with high gaba and peptide content using serial fermentation of bacillus and lactococcus |
KR20220072474A (en) * | 2020-11-25 | 2022-06-02 | 대상 주식회사 | Medium Composition for Producing Monacolin K, Method for Preparing Fermented Substance Using Same and Fermented Substance Prepared Thereby |
Also Published As
Publication number | Publication date |
---|---|
KR100970108B1 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5563550B2 (en) | Antioxidants and antioxidant beverages | |
KR20120125042A (en) | A process for preparing a fermented broth of herbal medicine by combined microorganisms, a fermented broth prepared by the process, and a fermented food prepared by the fermented broth | |
Rastogi et al. | Food fermentation–Significance to public health and sustainability challenges of modern diet and food systems | |
JP2005065691A (en) | COMPOSITION CONTAINING gamma-AMINOBUTYRIC ACID AND METHOD FOR MANUFACTURING THE SAME | |
KR20140033553A (en) | Functional persimmon vinegar and preparing method thereof | |
KR101616187B1 (en) | Method for manufacturing fermented beverage with Schisandra chinensis using GABA producing Lactobacillus | |
KR101865842B1 (en) | Lactic acid bacteria fermented rice comprising bay salt, preparation method thereof and kimchi sauce composition prepared thereby | |
CN105567533A (en) | Probiotic anti-oxidation health vinegar production method | |
KR100970108B1 (en) | Red coji ginseng and the producing method therof | |
KR101131069B1 (en) | Method for Preparing GABA-Containing Fermented Tomato Using Plant Originated Lactic Acid Bacteria with GABA-Producing Ability | |
CN106085789B (en) | Saffron and asparagus vinegar and preparation method and application thereof | |
KR20120064791A (en) | Method for producing vinegar comprising an effective compound derived from soybean and the vinegar produced by the same | |
KR101530661B1 (en) | Method for Preparing Makgeolli Using Monascus sp. and Makgeolli Prepared Thereby | |
CN101760477B (en) | Manufacturing method of blood pressure lowering red rice | |
KR101969708B1 (en) | Powder makgeolli composition containing DIY kit type lactic acid bacterium, method of preparing the composition, and makgeolli | |
KR100864786B1 (en) | Antioxidant composition comprising cereal fermented by bacillus sp. mab06 as an effective ingredient | |
JP4185823B2 (en) | Method for producing vinegar with high GABA (γ-aminobutyric acid) content | |
CN115777921A (en) | Preparation method of functional fruit and vegetable pulp and solid powder fermented by composite strain | |
KR20200145127A (en) | Composition and method for yogurt with enhanced GABA using barley and yogurt produced by the same | |
KR102409571B1 (en) | Method of manufacturing sweet flag vinegar using the barley nuruk and the sweet flag vinegar manufactured thereby | |
KR20220025678A (en) | Method for producing fermented barley sprout postbiotics with increased effective component content using lactic acid bacteria | |
KR100635132B1 (en) | Method for preparing of red-koji ginseng | |
KR101391632B1 (en) | Dried persimmon with functionality and preparing method thereof | |
KR20220025681A (en) | Method for producing fermented cranberry postbiotics with increased effective component content using lactic acid bacteria | |
CN112899117A (en) | Method for co-fermenting high gamma-aminobutyric acid red date and pearl barley vinegar by combining monascus with lactobacillus and spore bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |